Drug Trial Radar · NCT06109272
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
89
Actual
Start
Jan 11, 2024
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. In Stage 1, there are 3 treatment arms and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), atezolizumab in combination with bevacizumab, or tremelimumab in combination with durvalumab. In Stage 2, there are 2 treatments arms and participants will be randomized in a 1:1 ratio. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab or tremelimumab in combination with durvalumab. Approximately 660 adult participants will be enrolled in the study across 185 sites worldwide. Stage 1: In arm 1, participants will receive intravenously (IV) infused livmoniplimab (Dose 1) in combination with IV infused budigalimab, every 3 weeks. In arm 2, participants will receive IV infused livmoniplimab (Dose 2) in combination with IV infused budigalimab, every 3 weeks. In Arm 3 (control), participants will receive the investigator's choice: IV atezolizumab in combination with IV bevacizumab every 3 weeks or single dose IV tremelimumab in combination with IV durvalumab every 4 weeks. Stage 2: In arm 1, participants will receive IV infused livmoniplimab (optimized dose) in combination with IV infused budigalimab, every 3 weeks. In Arm 2 (control), participants will receive single dose IV tremelimumab in combination with IV durvalumab every 4 weeks. All participants will continue treatment until disease progression or discontinuation criteria are met, whichever occurs first. The estimated duration of this study is about 56 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Conditions
- Hepatocellular Carcinoma
Interventions
LivmoniplimabDrug
Intravenous (IV) Solution
BudigalimabDrug
Intravenous (IV) Solution
DurvalumabDrug
Intravenous (IV) Solution
AtezolizumabDrug
Intravenous (IV) Solution
BevacizumabDrug
Intravenous (IV) Solution
TremelimumabDrug
Intravenous (IV) Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Best Overall Response (BOR) per InvestigatorTime frame: Through Study Completion, Up to Approximately 56 Months
- Stage 2: Overall Survival (OS)Time frame: Through Study Completion, Up to Approximately 56 Months
Locations
37 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope /ID# 261468
Duarte, California
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 261669
Irvine, California
UC Irvine /ID# 255673
Orange, California
The University of Chicago Medical Center /ID# 255674
Chicago, Illinois
Alliance for Multispecialty Research LLC Kansas City Oncology /ID# 256830
Merriam, Kansas
Norton Cancer Institute /ID# 260775
Louisville, Kentucky
Henry Ford Hospital - Detroit /ID# 255803
Detroit, Michigan
Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041
Saint Louis Park, Minnesota
Washington University-School of Medicine /ID# 255720
St Louis, Missouri
Texas Oncology - Abilene - Antilley Road /ID# 265820
Abilene, Texas
Texas Oncology - Dallas - Worth Street /ID# 265806
Dallas, Texas
Baylor Scott and White Research Institute /ID# 260853
Dallas, Texas
Oncology and Hematology Associates of Southwest Virginia /ID# 265834
Roanoke, Virginia
Hopital Avicenne /ID# 266005
Bobigny, Île-de-France Region, France
Hopital Beaujon /ID# 256551
Clichy, Île-de-France Region, France
CHU Grenoble - Hopital Michallon /ID# 256627
La Tronche, Isere, France
Institut Gustave Roussy /ID# 258460
Villejuif, Val-de-Marne, France
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 256412
Bologna, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 256681
Palermo, Italy
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 256895
Roma, Italy
IRCCS Istituto Clinico Humanitas /ID# 256684
Rozzano, Lombardy, Italy
IRCCS Ospedale San Raffaele /ID# 256404
Milan, Milano, Italy
P.O. Ospedale del Mare /ID# 256410
Naples, Napoli, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 265506
Rome, Roma, Italy
Puerto Rico Medical Research Center /ID# 262362
Hato Rey, Puerto Rico, Puerto Rico
Hospital Universitario Vall de Hebron /ID# 255771
Barcelona, Spain
Hospital Universitario Reina Sofia /ID# 255779
Córdoba, Spain
Hospital General Universitario Gregorio Maranon /ID# 255772
Madrid, Spain
Hospital Universitario Virgen del Rocio /ID# 255776
Seville, Spain
Hospital Universitario Miguel Servet /ID# 255774
Zaragoza, Spain
Hospital Universitario Marques de Valdecilla /ID# 255769
Santander, Cantabria, Spain
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 255778
Majadahonda, Madrid, Spain
China Medical University Hospital /ID# 256764
Taichung, Taiwan
Taichung Veterans General Hospital /ID# 259405
Taichung, Taiwan
National Cheng Kung University Hospital /ID# 256766
Tainan, Taiwan
National Taiwan University Hospital /ID# 256168
Taipei, Taiwan
Taipei Veterans General Hosp /ID# 256169
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.